Replies to post #310518 on Avid Bioservices Inc (CDMO)

[biopharm]

I say Peregrine was involved with CSF1R inhibitor program and was nondisclosed ...

....Eli Lilly digging deeper into CSF1R and Peregrine must unveil a bit of their non disclosed collaborations


Colony-stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), is a cell-surface receptor for its ligands, colony-stimulating factor 1 (CSF1) and IL-34.1,2 CSF1R plays an important role as regulator of the development, morphology, survival, and functions of tissue macrophages as well as tumor-associated macrophages (TAMs). CSF1 is involved in the recruitment and survival of macrophages in tumors. Increased CSF1 expression is implicated in tumor progression and metastasis, and is associated with poor prognosis in some cancers.3
Molecule

LY3022855 (IMC-CS4) is a human IgG1 monoclonal antibody designed to target the CSF1R, preventing ligands CSF1 and IL-342 from binding to the receptor and inhibiting TAMs from receiving CSF1 signals, decreasing their survival and relieving the effect of TAMs in the tumor.4

How many non disclosed collaborations, being revealed....would help prove Ronin hedge fund is here only in light of some BP trying to steal PS Targeting.....

SNO has some CSF1R programs, listed below and the late Dr Andrew Parsa would have been here if he did not pass away....after the late Dr Phil Thorpe passed away all of a sudden

SNO

Nov 17, 2017



2:00-2:05pm CSF-1R inhibition ameliorates radiation-
RBIO-03 induced memory loss in a rodent glioma model
Feng X, Grue K, Liu S, Gupta N, Rosi S

...
...
https://www.soc-neuro-onc.org/SNO/My_SNO/2017_SNO_Annual_Meeting/SNO/2017Annual/2017AnnualHome.aspx

[biopharm]

Now I say Peregrine was involved with CSF1R inhibitor program and was nondisclosed ...

....Eli Lilly digging deeper into CSF1R and Peregrine must unveil a bit of their non disclosed collaborations


Colony-stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), is a cell-surface receptor for its ligands, colony-stimulating factor 1 (CSF1) and IL-34.1,2 CSF1R plays an important role as regulator of the development, morphology, survival, and functions of tissue macrophages as well as tumor-associated macrophages (TAMs). CSF1 is involved in the recruitment and survival of macrophages in tumors. Increased CSF1 expression is implicated in tumor progression and metastasis, and is associated with poor prognosis in some cancers.3
Molecule

LY3022855 (IMC-CS4) is a human IgG1 monoclonal antibody designed to target the CSF1R, preventing ligands CSF1 and IL-342 from binding to the receptor and inhibiting TAMs from receiving CSF1 signals, decreasing their survival and relieving the effect of TAMs in the tumor.4

Clinical Development

LY3022855 (IMC-CS4) is being investigated in phase I clinical trials, including a collaboration clinical trial with another immuno-oncology agent.

http://www.lillyoncologypipeline.com/molecule/csf-1-r-antibody/overview

The new BODs have failed in full contract disclosures and failed big time in not having the IP assets evaluated fully AND a much more public, open bid that would have brought much bigger early dollars and avoided a RS

Eli Lilly must be just lucky ...or not